Companion Diagnostics (CDx) and Clinical Trial Support

SHARE

After marker identification, biomarkers and/or gene signatures enter our development process to become targeted assays.  The newly identified biomarkers are developed into a Laboratory Developed Test (LDT) that will be run in Exosome Diagnostic’s CLIA and CAP accredited laboratory.

Most popular related searches

Tissue & Additional Services

Exosome Diagnostics also offers additional biomarker testing services that are not exosome based, such as soluble protein and cell free DNA (cfDNA) analysis.  We can utilize tissue, FFPE, whole blood, cell culture materials or other sample types for protein and nucleic acid analysis.